abstract |
The present invention relates to the identification of a microRNA, miR-21, that alters energy metabolism in cardiomyocytes and thus contributes to cardiac remodeling. Inhibition of this function is proposed as a treatment for cardiac hypertrophy, heart failure, and/or myocardial infarction. |